Tarsus Pharmaceuticals Q3 EPS $(1.28) Vs $(0.84) Last Year, Sales $1.87M Beat $399.8K Estimate
Portfolio Pulse from Benzinga Newsdesk
Tarsus Pharmaceuticals reported Q3 earnings per share (EPS) of $(1.28), compared to $(0.84) last year. However, the company's sales of $1.87M surpassed the estimate of $399.8K.
November 09, 2023 | 9:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Tarsus Pharmaceuticals reported a higher loss per share in Q3 compared to last year, but sales significantly exceeded estimates.
Tarsus Pharmaceuticals reported a higher loss per share in Q3 compared to last year, which could negatively impact the stock. However, the company's sales significantly exceeded estimates, which could offset the negative impact of the higher loss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100